Historical Archive

ABOUTPHARMA, Press Review from 20/01/09 to 22/01/09

Press Review from 20/01/09 to the 22/01/09 


In 2008, Abbott earned $5 billion

(International Herald Tribune: p. 13, The Wall Street Journal online, Les Echos online - January 22, 2009)

Abbott closed 2008 on a positive note: net income increased by 35% to $4.8 billion and turnover increased by 13.9% to $29.5 billion. In the 4th quarter, net income increased 28%, driven primarily by sales of arthritis drug Humira (adalimumab). For 2009, Abbott estimates earnings per share of between $3.35 and $3.70.



EU: Roche's drug for rheumatoid arthritis approved

(The Wall Street Journal online - January 22, 2009)

The European Union has approved the marketing of RoActemra (tocilizumab), a drug for the treatment of rheumatoid arthritis co-developed by Roche and its Japanese subsidiary Chugai. The medicine will be combined with another drug in adult patients who are unresponsive or intolerant to other therapies.



US: 635 million dollars to eradicate polio

(The Wall Street Journal

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco